Tags : Aldeyra Therapeutics

Aldeyra Therapeutics to Advance ADX-1612 to Clinical Testing and Provides

Shots: Aldeyra has reported the planned advancement of ADX-1612 (HSP90 inhibitor) to clinical testing for COVID-19, and provided an update on ADX-629 (RASP inhibitor) for COVID-19 and other inflammatory diseases ADX-1612 has demonstrated nanomolar potency like or greater than Gilead’s remdesivir in an in vitro model and acts by inhibiting the proteins associated with viral […]Read More